AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3484922 — intervention group
Group type: COMPARATOR
Intervention: Mesocaval shunt (MS)
Number of subjects: 80
Study 31397647 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured program of exercise training (walking, aerobic, strength-conditioning, relaxation exercises) during pregnancy
Number of subjects: 170
Study 31397647 — intervention group
Group type: COMPARATOR
Intervention: Control group (no structured exercise intervention)
Number of subjects: 170
Study 30360881 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatty fish (n=114)
Number of subjects: 232
Study 30360881 — intervention group
Group type: COMPARATOR
Intervention: Meat (n=118)
Number of subjects: 232
Study 26951702 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel administration directly from the cardiology unit at each monitoring visit
Number of subjects: 784
Study 26951702 — intervention group
Group type: COMPARATOR
Intervention: Standard retail pharmacy channel prescription
Number of subjects: 784
Study 25016276 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT) and General exercises
Number of subjects: 54
Study 25016276 — intervention group
Group type: COMPARATOR
Intervention: General exercises
Number of subjects: 54
Study 22430920 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine (1.0–2.0 mg on the first day, followed by 0.5–1.0 mg/day for 6 months)
Number of subjects: 120
Study 22430920 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 22430920 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine
Number of subjects: 120
Study 22430920 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine and Placebo
Number of subjects: 120
Study 19633042 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose adecatumumab (6 mg/kg every two weeks)
Number of subjects: 109
Study 19633042 — intervention group
Group type: COMPARATOR
Intervention: Low-dose adecatumumab (2 mg/kg every two weeks)
Number of subjects: 109
Study 19633042 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose adecatumumab
Number of subjects: 109
Study 19633042 — intervention group
Group type: COMPARATOR
Intervention: Low-dose adecatumumab
Number of subjects: 109
Study 18493207 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 5 mg
Number of subjects: 109
Study 18493207 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 10 mg
Number of subjects: 109
Study 18493207 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 10 mg (for children >=20 kg)
Number of subjects: 109
Study 18493207 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg (for children >=20 kg)
Number of subjects: 109
Study 18493207 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole (all doses)
Number of subjects: 109
Study 15931231 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg/day IL-1ra
Number of subjects: 91
Study 15931231 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study 12595860 — intervention group
Group type: EXPERIMENTAL
Intervention: NIR stent (second-generation stainless steel stent)
Number of subjects: 424
Study 12595860 — intervention group
Group type: COMPARATOR
Intervention: PS stent (first-generation Palmaz-Schatz stent)
Number of subjects: 424
Study 12595860 — intervention group
Group type: EXPERIMENTAL
Intervention: NIR stent
Number of subjects: 424
Study 12595860 — intervention group
Group type: COMPARATOR
Intervention: PS stent
Number of subjects: 424
Study 10532204 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal circulation (ECC)
Number of subjects: 25
Study 10532204 — intervention group
Group type: COMPARATOR
Intervention: Surgical intervention (control group B)
Number of subjects: 25
Study 8679463 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative chemotherapy (5-fluorouracil, doxorubicin, cyclophosphamide)
Number of subjects: 441
Study 8679463 — intervention group
Group type: COMPARATOR
Intervention: No perioperative chemotherapy
Number of subjects: 441
Study 1563329 — intervention group
Group type: EXPERIMENTAL
Intervention: Muesli (slow release starch: SRS)
Number of subjects: 14
Study 1563329 — intervention group
Group type: COMPARATOR
Intervention: Cornflakes (fast release starch: FRS)
Number of subjects: 14
Study 3913726 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoprofen calcium (doses between 12.5 and 300 mg)
Number of subjects: 867
Study 3913726 — intervention group
Group type: COMPARATOR
Intervention: Codeine sulfate (60 mg)
Number of subjects: 867
Study 3913726 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 867
Study 31164602 — intervention group
Group type: EXPERIMENTAL
Intervention: School-Based Sexual and Reproductive Health (SBSRH) interventions including tailored SRH information, in-school medical care, and referral over 12 months.
Number of subjects: 1080
Study 31164602 — intervention group
Group type: COMPARATOR
Intervention: No intervention from the research team (control group).
Number of subjects: 1080
Study 29238974 — intervention group
Group type: EXPERIMENTAL
Intervention: DEE (docetaxel, epirubicin, and rh-endostatin)
Number of subjects: 803
Study 29238974 — intervention group
Group type: COMPARATOR
Intervention: DE (docetaxel and epirubicin)
Number of subjects: 803
Study 27431042 — intervention group
Group type: EXPERIMENTAL
Intervention: MIA: STEP
Number of subjects: 450
Study 27431042 — intervention group
Group type: COMPARATOR
Intervention: SAU
Number of subjects: 450
Study 23106157 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal injection of 1.5 mL (250 MU) of BTX‐A
Number of subjects: 11
Study 23106157 — intervention group
Group type: COMPARATOR
Intervention: Iontophoresis of BTX‐A
Number of subjects: 11
Study 22296885 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acid supplementation (OMACOR fish oil, 850-882 mg eicosapentaenoic and docosahexaenoic acid)
Number of subjects: 150
Study 21434529 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alpha (IFN‐alpha2a) 5 MU/m2 to 10 MU/m2 for six months and lamivudine (4 mg/kg/day)
Number of subjects: 38
Study 18025857 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithotomy position (LP)
Number of subjects: 340
Study 18025857 — intervention group
Group type: COMPARATOR
Intervention: Left lateral decubitis position (LLDP)
Number of subjects: 340
Study 18025857 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 3 (LP and LLDP)
Number of subjects: 340
Study 18025857 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 4 (LLDP and LP)
Number of subjects: 340
Study 15755593 — intervention group
Group type: EXPERIMENTAL
Intervention: MeNZB™ vaccine
Number of subjects: 4
Study 12126287 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion for smoking cessation (exact dosage and duration not specified)
Number of subjects: 66
Study 12126287 — intervention group
Group type: COMPARATOR
Intervention: Non-randomized participants (control group)
Number of subjects: 66
Study 11593579 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery with postoperative radiotherapy (16 patients)
Number of subjects: 29
Study 11593579 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone (13 patients)
Number of subjects: 29
Study 8523110 — intervention group
Group type: EXPERIMENTAL
Intervention: 125I-chimeric 17-1A antibody, administered in doses of 20, 40, 60, 80, 100, 150, 200, or 250 mCi, with infusions at 4-day intervals.
Number of subjects: 28
Study 1842236 — intervention group
Group type: EXPERIMENTAL
Intervention: Butter and milk diet (300 mg cholesterol and 95 g fat)
Number of subjects: 24
Study 1842236 — intervention group
Group type: EXPERIMENTAL
Intervention: Single egg diet (300 mg cholesterol and 6 g fat)
Number of subjects: 24
Study 1842236 — intervention group
Group type: EXPERIMENTAL
Intervention: Crystalline cholesterol with 200 ml milk (1020 mg cholesterol and 14 g fat)
Number of subjects: 24
Study 7183209 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at traditional loci (right side GB-20, both sides EH-6, both sides St-36)
Number of subjects: 40
Study 7183209 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture at non-acupuncture loci (self-control study)
Number of subjects: 40
Study 31778630 — intervention group
Group type: EXPERIMENTAL
Intervention: Low tidal volume (6 mL/kg predicted body weight)
Number of subjects: 1240
Study 31778630 — intervention group
Group type: COMPARATOR
Intervention: Conventional tidal volume (10 mL/kg predicted body weight)
Number of subjects: 1240
Study 29701662 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic drink containing 10 billion Lactobacillus casei, administered as two bottles daily via feeding tube.
Number of subjects: 32
Study 29701662 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified what the control was).
Number of subjects: 32
Study 29701662 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic drink containing 10 billion Lactobacillus casei.
Number of subjects: 32
Study 26418784 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BTX‐A)
Number of subjects: 26
Study 26418784 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 26
Study 26418784 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of upper and lower forehead VAS scores
Number of subjects: 26
Study 26418784 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall comparison of BTX‐A vs control
Number of subjects: 26
Study 24439982 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoprostenol with arginine and sucrose excipients (Veletri)
Number of subjects: 41
Study 22920991 — intervention group
Group type: COMPARATOR
Intervention: Standard Care (brief advice to quit smoking, nicotine replacement therapy, self-help materials)
Number of subjects: 756
Study 22920991 — intervention group
Group type: COMPARATOR
Intervention: Enhanced Care (standard care plus cell phone-delivered text/graphical messaging)
Number of subjects: 756
Study 22920991 — intervention group
Group type: COMPARATOR
Intervention: Intensive Care (enhanced care plus 11 proactive counseling sessions via cell phone)
Number of subjects: 756
Study 20207829 — intervention group
Group type: EXPERIMENTAL
Intervention: IGF‐I target of 2 SDS (IGF2T)
Number of subjects: 165
Study 20207829 — intervention group
Group type: EXPERIMENTAL
Intervention: IGF‐I target of 0 SDS (IGF0T)
Number of subjects: 165
Study 20207829 — intervention group
Group type: COMPARATOR
Intervention: Conventional weight‐based GH dosing of 40 microg/kg x d (Conv)
Number of subjects: 165
Study 17673873 — intervention group
Group type: EXPERIMENTAL
Intervention: LVEDP >30 mm Hg (n=187)
Number of subjects: 744
Study 17673873 — intervention group
Group type: COMPARATOR
Intervention: Other cohorts combined (n=603)
Number of subjects: 744
Study 15670485 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 144
Study 15670485 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study 11893636 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodixanol (150 mgI ml(‐1) and 320 mgI ml(‐1))
Number of subjects: 154
Study 11893636 — intervention group
Group type: COMPARATOR
Intervention: Iohexol (140 mgI ml(‐1) and 300 mgI ml(‐1))
Number of subjects: 154
Study 11893636 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodixanol
Number of subjects: 154
Study 11893636 — intervention group
Group type: COMPARATOR
Intervention: Iohexol
Number of subjects: 154
Study 9527073 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 410
Study 9527073 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 410
Study 9527073 — intervention group
Group type: COMPARATOR
Intervention: Beta blockers, calcium antagonists, or nitrates
Number of subjects: 410
Study 7843454 — intervention group
Group type: EXPERIMENTAL
Intervention: Five milliliters of 2% mepivacaine
Number of subjects: 45
Study 7843454 — intervention group
Group type: COMPARATOR
Intervention: Saline solution
Number of subjects: 45
Study 2142858 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptide (ANP) 5 ng.kg‐1.min‐1, n = 9
Number of subjects: 16
Study 2142858 — intervention group
Group type: COMPARATOR
Intervention: Placebo (isotonic saline, n = 7)
Number of subjects: 16
Study 455981 — intervention group
Group type: EXPERIMENTAL
Intervention: Paper formulation of oral contraceptive
Number of subjects: 0
Study 455981 — intervention group
Group type: COMPARATOR
Intervention: Conventional tablet
Number of subjects: 0
Study 31841744 — intervention group
Group type: EXPERIMENTAL
Intervention: HPD-BCX (energy-restricted HPD + BCX)
Number of subjects: 92
Study 31841744 — intervention group
Group type: COMPARATOR
Intervention: Control (standard energy-restricted diet + placebo)
Number of subjects: 92
Study 30685287 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete CHOICE
Number of subjects: 1008
Study 30685287 — intervention group
Group type: COMPARATOR
Intervention: Enhanced Care
Number of subjects: 1008
Study 27967294 — intervention group
Group type: EXPERIMENTAL
Intervention: Myeloid growth factors (GF) administered to 256 patients (49%)
Number of subjects: 520
Study 27967294 — intervention group
Group type: COMPARATOR
Intervention: CHOP or R‐CHOP treatment
Number of subjects: 520
Study 27967294 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors for FN
Number of subjects: 520
Study 26351990 — intervention group
Group type: EXPERIMENTAL
Intervention: Foster care intervention
Number of subjects: 3
Study 26351990 — intervention group
Group type: COMPARATOR
Intervention: Prolonged institutional rearing (control)
Number of subjects: 3
Study 26351990 — intervention group
Group type: COMPARATOR
Intervention: Never-institutionalized children (control)
Number of subjects: 3
Study 24089542 — intervention group
Group type: EXPERIMENTAL
Intervention: Jet injection of insulin aspart
Number of subjects: 24
Study 24089542 — intervention group
Group type: COMPARATOR
Intervention: Conventional insulin pen
Number of subjects: 24
Study 19775782 — intervention group
Group type: EXPERIMENTAL
Intervention: EP group (diet and physical activity education from 16 gestational weeks to six months post partum)
Number of subjects: 189
Study 19775782 — intervention group
Group type: EXPERIMENTAL
Intervention: EPP group (diet and physical activity education from 24-48 hours after birth to six months post partum)
Number of subjects: 189
Study 19775782 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (routine outpatient department obstetric educational programme)
Number of subjects: 189
Study 19267286 — intervention group
Group type: EXPERIMENTAL
Intervention: Water drinking at a rate of 10 ml/min
Number of subjects: 0
Study 19267286 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrient liquid drinking at a rate of 100 ml/min
Number of subjects: 0
Study 19267286 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrient liquid drinking at a rate of 20 ml/min
Number of subjects: 0
Study 19267286 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow nutrient drinking
Number of subjects: 0
Study 16700685 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided Participation (GP)
Number of subjects: 16
Study 16700685 — intervention group
Group type: COMPARATOR
Intervention: Standard Care Teaching
Number of subjects: 16
Study 15612345 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyanoacrylate adhesive debonded within 30 minutes after bonding
Number of subjects: 60
Study 15612345 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyanoacrylate adhesive debonded after 24 hours immersion in deionized water at 37 degrees C
Number of subjects: 60
Study 15612345 — intervention group
Group type: COMPARATOR
Intervention: Cyanoacrylate adhesive debonded after 30 days immersion in deionized water at 37 degrees C
Number of subjects: 60
Study 12439363 — intervention group
Group type: EXPERIMENTAL
Intervention: Preprocedural hydration, amount of dye administered, and postprocedural therapies
Number of subjects: 0
Study 9129960 — intervention group
Group type: EXPERIMENTAL
Intervention: 4‐3 and 4‐4 apoE phenotypes
Number of subjects: 1751
Study 9129960 — intervention group
Group type: EXPERIMENTAL
Intervention: epsilon 4 allele
Number of subjects: 1751
Study 9129960 — intervention group
Group type: COMPARATOR
Intervention: apoE phenotype
Number of subjects: 1751
Study 7893582 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (20 mg daily for 2 weeks)
Number of subjects: 0
Study 7893582 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7893582 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline
Number of subjects: 0
Study 2850682 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (mean daily dose: 56 +/- 2 mg)
Number of subjects: 24
Study 2850682 — intervention group
Group type: COMPARATOR
Intervention: Enalapril (mean daily dose: 9.6 +/- 0.9 mg)
Number of subjects: 24
Study 29878501 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-mg/day doxazosin
Number of subjects: 35
Study 29878501 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin (4-mg/day and 8-mg/day)
Number of subjects: 35
Study 29878501 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin (8-mg/day)
Number of subjects: 35
Study 29878501 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 27167378 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological counseling and educational intervention
Number of subjects: 698
Study 27167378 — intervention group
Group type: COMPARATOR
Intervention: Routine directly-observed anti-TB therapy
Number of subjects: 698
Study 26189139 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary treatment with α1-blockers for 8 weeks
Number of subjects: 79
Study 23784467 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary therapy of qi-yin-reinforcing porridge
Number of subjects: 14
Study 23784467 — intervention group
Group type: COMPARATOR
Intervention: Dextrin-prepared porridge (placebo control)
Number of subjects: 14
Study 21155047 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-injection femoral nerve block with 0.25% levobupivacaine (30 mL) combined with epidural analgesia
Number of subjects: 78
Study 21155047 — intervention group
Group type: COMPARATOR
Intervention: Epidural analgesia alone (control group)
Number of subjects: 78
Study 18196898 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine
Number of subjects: 36
Study 18196898 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 17283003 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable defibrillator (ICD)
Number of subjects: 1866
Study 17283003 — intervention group
Group type: COMPARATOR
Intervention: Amiodarone
Number of subjects: 1866
Study 15646486 — intervention group
Group type: EXPERIMENTAL
Intervention: Nyolol Gel 0,1%
Number of subjects: 192
Study 15646486 — intervention group
Group type: COMPARATOR
Intervention: Regular timolol treatment (Ofterisin 0,5%)
Number of subjects: 192
Study 15646486 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol 0,1% gel formulation
Number of subjects: 192
Study 15646486 — intervention group
Group type: COMPARATOR
Intervention: Timolol aqueous eye drops
Number of subjects: 192
Study 11349617 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (5-10 mg/day)
Number of subjects: 244
Study 11349617 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine (40-80 mg/day)
Number of subjects: 244
Study 9192486 — intervention group
Group type: EXPERIMENTAL
Intervention: Left ventricular assist devices
Number of subjects: 0
Study 9192486 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical therapy
Number of subjects: 0
Study 9192486 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 0
Study 9192486 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic cardiomyoplasty
Number of subjects: 0
Study 9192486 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial left ventricular resection
Number of subjects: 0
Study 8216503 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotinic acid (1 g t.d.s.)
Number of subjects: 0
Study 8216503 — intervention group
Group type: EXPERIMENTAL
Intervention: Acipimox (placebo controlled)
Number of subjects: 0
Study 3301913 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine gluconate mouthwash used 3 times daily
Number of subjects: 0
Study 3301913 — intervention group
Group type: COMPARATOR
Intervention: Placebo mouthwash
Number of subjects: 0
Study 3301913 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine gluconate mouthwash
Number of subjects: 0
Study 31874512 — intervention group
Group type: EXPERIMENTAL
Intervention: del Nido cardioplegia
Number of subjects: 84
Study 31874512 — intervention group
Group type: COMPARATOR
Intervention: Thomas cardioplegia
Number of subjects: 84
Study 28679349 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT + HT
Number of subjects: 51
Study 28679349 — intervention group
Group type: COMPARATOR
Intervention: CRT alone
Number of subjects: 51
Study 27676398 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 335
Study 24172721 — intervention group
Group type: EXPERIMENTAL
Intervention: Uphill interval treadmill training (GHill)
Number of subjects: 32
Study 24172721 — intervention group
Group type: EXPERIMENTAL
Intervention: Level-grade interval treadmill training (GFlat)
Number of subjects: 32
Study 24172721 — intervention group
Group type: COMPARATOR
Intervention: Control group (GCon)
Number of subjects: 32
Study 22651572 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard GH dose (43 μg/kg/day)
Number of subjects: 127
Study 22651572 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized GH dose (17‐100 μg/kg/day)
Number of subjects: 127
Study 19924675 — intervention group
Group type: EXPERIMENTAL
Intervention: Test dexchlorpheniramine 2.0 mg tablet (Eurofarma)
Number of subjects: 0
Study 19924675 — intervention group
Group type: COMPARATOR
Intervention: Reference dexchlorpheniramine 2.0 mg tablet (Celestamine, Schering‐Plough)
Number of subjects: 0
Study 18577692 — intervention group
Group type: COMPARATOR
Intervention: Lower insulinemic-euglycemic clamp (100 pmol/l insulin, 5 mmol/l glucose)
Number of subjects: 6
Study 18577692 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperinsulinemic-euglycemic clamp (400 pmol/l insulin, 5 mmol/l glucose)
Number of subjects: 6
Study 18577692 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower insulinemic-hyperglycemic clamp (100 pmol/l insulin, 12 mmol/l glucose)
Number of subjects: 6
Study 18577692 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperinsulinemic-hyperglycemic clamp (400 pmol/l insulin, 12 mmol/l glucose)
Number of subjects: 6
Study 15813287 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg once daily
Number of subjects: 0
Study 15813287 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0